<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">PEN</journal-id>
<journal-id journal-id-type="hwp">sppen</journal-id>
<journal-id journal-id-type="nlm-ta">JPEN J Parenter Enteral Nutr</journal-id>
<journal-title>Journal of Parenteral and Enteral Nutrition</journal-title>
<issn pub-type="ppub">0148-6071</issn>
<issn pub-type="epub">1941-2444</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0148607111420154</article-id>
<article-id pub-id-type="publisher-id">10.1177_0148607111420154</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Original Communications</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Calcium Chloride and Sodium Phosphate in Neonatal Parenteral Nutrition Containing TrophAmine</article-title>
<subtitle>Precipitation Studies and Aluminum Content</subtitle>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Migaki</surname><given-names>Evelyn A.</given-names></name>
<degrees>RPh</degrees>
<xref ref-type="aff" rid="aff1-0148607111420154">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Melhart</surname><given-names>Brian J.</given-names></name>
<degrees>PharmD</degrees>
<xref ref-type="aff" rid="aff1-0148607111420154">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Dewar</surname><given-names>Christina J.</given-names></name>
<degrees>PharmD, BCPS</degrees>
<xref ref-type="aff" rid="aff2-0148607111420154">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Huston</surname><given-names>Robert K.</given-names></name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff3-0148607111420154">3</xref>
</contrib>
</contrib-group>
<aff id="aff1-0148607111420154"><label>1</label>Providence St Vincent Medical Center, Portland, Oregon</aff>
<aff id="aff2-0148607111420154"><label>2</label>Aultman Hospital, Canton, Ohio</aff>
<aff id="aff3-0148607111420154"><label>3</label>The Children’s Hospital at Legacy Emanuel Medical Center, Portland, Oregon</aff>
<author-notes>
<corresp id="corresp1-0148607111420154">Evelyn A. Migaki, Providence St Vincent Medical Center, 9205 SW Barnes Rd, Portland, OR 97225 e-mail: <email>Evelyn.Migaki@providence.org</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>7</month>
<year>2012</year>
</pub-date>
<volume>36</volume>
<issue>4</issue>
<fpage>470</fpage>
<lpage>475</lpage>
<history>
<date date-type="received">
<day>21</day>
<month>3</month>
<year>2011</year>
</date>
<date date-type="accepted">
<day>26</day>
<month>6</month>
<year>2011</year>
</date>
</history>
<permissions>
<copyright-statement>© 2012 American Society for Parenteral and Enteral Nutrition</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="society">The American Society for Parenteral and Enteral Nutrition</copyright-holder>
</permissions>
<abstract>
<p><italic>Objectives</italic>: The objectives were to determine concentrations of calcium chloride (CaCl) and sodium phosphate (NaPhos) that can be safely added to TrophAmine-based parenteral nutrition (PN) and to measure aluminum (Al) concentrations in PN solutions containing CaCl and NaPhos vs those containing calcium gluconate (CaGlu) and potassium phosphate (KPhos). <italic>Methods</italic>: In study A, PN solutions containing varying amounts of TrophAmine, CaCl, and NaPhos were compounded and then evaluated visually for precipitation. In study B, Al concentrations were measured in PN solutions containing CaCl and NaPhos (S1), CaGlu and NaPhos (S2), or CaGlu and KPhos (S3). <italic>Results</italic>: Study A showed that a maximum phosphorus concentration of 15 mmol/L could be added to a solution containing 12.5 mmol/L of calcium without evidence of precipitation when the amino acid (AA) concentration reached ≥3 g/dL (3%). In study B, the mean (range) Al concentrations were S1 = 2.2 (1.9–2.4), S2 = 8.5 (7.8–9.3), and S3 = 11.7 (10.8–12.2) µmol/L (means of 6.0, 22.9, and 31.5 micrograms/dL, respectively). <italic>Conclusions</italic>: The data can provide a guide for compounding neonatal PN solutions containing TrophAmine, CaCl, and NaPhos. More studies are needed to determine the long-term effects of substituting CaCl for CaGlu in PN solutions for neonates. Substituting CaCl and NaPhos for CaGlu and KPhos significantly decreases Al concentrations in PN and potential Al exposure of neonatal patients.</p>
</abstract>
<kwd-group>
<kwd>neonates</kwd>
<kwd>parenteral formulas</kwd>
<kwd>parenteral nutrition</kwd>
<kwd>minerals/trace elements</kwd>
<kwd>aluminum</kwd>
<kwd>calcium chloride</kwd>
<kwd>precipitation studies</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-0148607111420154">
<title>Clinical Relevancy Statement</title>
<p>It has been difficult to meet the Food and Drug Administration (FDA) recommendation of limiting aluminum (Al) exposure in preterm infants due to significant Al contamination of additives to parenteral nutrition (PN). Calcium gluconate (CaGlu) and potassium phosphate (KPhos) are major contributors to Al contamination, but precipitation studies for neonatal TrophAmine-based PN solutions made with low Al containing calcium chloride (CaCl) and sodium phosphate (NaPhos) have not been available. This article reports the results of precipitation studies for neonatal PN solutions made with TrophAmine, CaCl, and NaPhos, which can be used as a guide for safe compounding of neonatal PN solutions to decrease Al exposure in neonatal patients. The article also reconfirms that PN solutions made with CaCl and NaPhos, as opposed to CaGlu and KPhos, can limit Al intake to near FDA recommended intakes.</p>
</sec>
<sec id="section2-0148607111420154" sec-type="intro">
<title>Introduction</title>
<p>Parenteral nutrition (PN) is a vital alternative therapy for patients of all ages who are unable to receive adequate nutrition orally and/or enterally. In 1997, Bishop et al<sup><xref ref-type="bibr" rid="bibr1-0148607111420154">1</xref></sup> reported an association between impaired neurological development of neonates and aluminum (Al) exposure from the PN solutions. A follow-up study also associated high Al exposure from PN solutions with reduced bone mass in adolescence.<sup><xref ref-type="bibr" rid="bibr2-0148607111420154">2</xref></sup> Al is a contaminant introduced into many small- and large-volume parenteral products during the manufacturing process, as well as due to leaching of Al during sterilization of glass containers.<sup><xref ref-type="bibr" rid="bibr3-0148607111420154">3</xref></sup> Calcium gluconate (CaGlu) is commonly used in PN solutions because it decreases the dissociation of calcium cations into the solution, thereby decreasing the risk of forming precipitates with phosphate, compared to calcium chloride (CaCl).<sup><xref ref-type="bibr" rid="bibr4-0148607111420154">4</xref></sup> The concentrations of calcium and phosphorus used in PN solutions to support neonatal patients increase the risk of precipitation.<sup><xref ref-type="bibr" rid="bibr5-0148607111420154">5</xref></sup> However, PN solutions made with CaCl contain significantly less Al compared to those made with CaGlu. In an effort to decrease neonatal patient risk from Al exposure in PN, CaCl has been substituted for CaGlu.<sup><xref ref-type="bibr" rid="bibr1-0148607111420154">1</xref></sup></p>
<p>Several factors have been identified that affect the solubility of calcium and phosphate in PN solutions, including the amount of calcium and phosphate added to the solutions, the form of calcium salt used, amino acid (AA) concentration, AA composition, solution pH, time in solution, temperature, and the order in which calcium and phosphate are added.<sup><xref ref-type="bibr" rid="bibr4-0148607111420154">4</xref>,<xref ref-type="bibr" rid="bibr6-0148607111420154">6</xref></sup> Numerous studies have been conducted to account for these variables, resulting in published calcium-phosphate precipitation curves.<sup><xref ref-type="bibr" rid="bibr4-0148607111420154">4</xref>,<xref ref-type="bibr" rid="bibr6-0148607111420154">6</xref><xref ref-type="bibr" rid="bibr7-0148607111420154"/>-<xref ref-type="bibr" rid="bibr8-0148607111420154">8</xref></sup> Methods for determining the presence of calcium-phosphate precipitates include visual inspection, microscopic inspection, spectrophotometry, filterization, and laser analysis.<sup><xref ref-type="bibr" rid="bibr4-0148607111420154">4</xref>,<xref ref-type="bibr" rid="bibr7-0148607111420154">7</xref>,<xref ref-type="bibr" rid="bibr9-0148607111420154">9</xref>,<xref ref-type="bibr" rid="bibr10-0148607111420154">10</xref></sup> Published calcium-phosphate precipitation curves are most commonly based on CaGlu or a combination of calcium salts.<sup><xref ref-type="bibr" rid="bibr4-0148607111420154">4</xref>,<xref ref-type="bibr" rid="bibr6-0148607111420154">6</xref><xref ref-type="bibr" rid="bibr7-0148607111420154"/>-<xref ref-type="bibr" rid="bibr8-0148607111420154">8</xref></sup> Because the calcium salt and AA source used to compound the PN solution are major factors influencing precipitation, these CaGlu-based curves cannot be safely applied to PN solutions compounded with CaCl. The presence or absence of L-cysteine in PN solutions is another variable in precipitation studies that must be accounted for because cysteine has also been shown to increase the solubility of calcium and phosphorus due to a decrease in the pH of the PN solution.<sup><xref ref-type="bibr" rid="bibr10-0148607111420154">10</xref></sup> Although a recent precipitation curve for neonatal PN containing CaCl and sodium phosphate (NaPhos) has been published,<sup><xref ref-type="bibr" rid="bibr11-0148607111420154">11</xref></sup> no calcium-phosphate precipitation curves using CaCl and NaPhos in a TrophAmine-based (Braun Medical, Inc, Irvine, CA) solution have been published.</p>
<p>We have been using CaCl and NaPhos in our neonatal PN containing TrophAmine since 2000. We have conducted precipitation studies in the pharmacy over the past 10 years to determine acceptable amounts of CaCl and NaPhos that can be safely added to PN solutions containing various concentrations of TrophAmine. The first objective of the studies reported in this article was to determine the maximum concentrations of CaCl and NaPhos that may be used in TrophAmine-based neonatal PN solutions without the risk of precipitate formation. A second objective was to determine Al concentrations in PN solutions containing CaCl and NaPhos vs solutions containing CaGlu and potassium phosphate (KPhos).</p>
</sec>
<sec id="section3-0148607111420154" sec-type="methods">
<title>Methods</title>
<p>Study A was conducted to determine the maximum concentrations of CaCl and NaPhos that may be used in TrophAmine-based neonatal PN solutions without the risk of precipitate formation. This study was performed in 2 parts. In part 1, solutions with final AA concentrations of 1%, 1.5%, 2%, 2.5%, and 3% TrophAmine were compounded by a PharmD resident in May–June 2007. To obtain data for AA concentrations between 2.5% and 3%, as well as higher AA concentrations, additional studies using concentrations of 2.8%, 3.5%, and 4% TrophAmine were conducted in February 2010 by a second PharmD resident. Heparin was added to the solutions studied in 2007 but not in 2010. The pH of heparin additives is adjusted to 5.0–7.5, whereas the pH of TrophAmine is 5.0–6.0. The volume of heparin is 0.5 mL (per 100 mL of solution) compared to 28–40 mL of TrophAmine (per 100 mL of solution). At the higher AA concentrations used in 2010, the effect of this relatively small volume of heparin on pH and precipitation would most likely be negligible.</p>
<p>Except for the concentrations of AA and heparin, the same procedures were followed for both parts of this study. Sample solutions were prepared in a laminar flow hood at room temperature using a Baxa ExactaMix 2400 Compounder (Baxa Corporation, Englewood, CO). PN solutions for the study were compounded in 100-mL aliquots using dextrose, magnesium sulfate, standard trace elements, and selenium with varying concentrations of TrophAmine, CaCl, NaPhos, and sterile water for injection (<xref ref-type="table" rid="table1-0148607111420154">Table 1</xref>). Calcium (as CaCl) concentrations of 2.5, 5, 7.5, 10, and 12.5 mmol/L and phosphorus (as NaPhos) concentrations of 5, 7.5, 10, 15, and 20 mmol/L were studied. No lipid emulsion was included since we do not use 3-in-1 solutions for neonatal PN.</p>
<table-wrap id="table1-0148607111420154" position="float">
<label>Table 1.</label>
<caption><p>Parenteral Nutrition Additives for Precipitation Studies</p></caption>
<graphic alternate-form-of="table1-0148607111420154" xlink:href="10.1177_0148607111420154-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left">Additive</th>
<th align="center">Manufacturer</th>
<th align="center">Total Dose</th>
<th align="center">Volume Added</th>
<th align="center">Additive Aluminum Content, µmol/L (µg/L)</th>
<th align="center">Solution Aluminum Content, µmol/dL (µg/dL)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dextrose 70%</td>
<td>Hospira, Inc (Lake Forest, IL)</td>
<td>10 g</td>
<td>14.3 mL</td>
<td>0.93 (25)</td>
<td>0.013 (0.357)</td>
</tr>
<tr>
<td>TrophAmine 10%</td>
<td>Braun Medical, Inc (Irvine, CA)</td>
<td>3 g<sup><xref ref-type="table-fn" rid="table-fn1-0148607111420154">a</xref></sup></td>
<td>30 mL</td>
<td>0.93 (25)</td>
<td>0.028 (0.028)</td>
</tr>
<tr>
<td>Sterile water</td>
<td>Hospira, Inc</td>
<td>QS to 100 mL</td>
<td>QS to 100 mL</td>
<td>0.93 (25)</td>
<td align="center">—</td>
</tr>
<tr>
<td>Heparin, 100 units/mL</td>
<td>BD Pharmaceuticals (Franklin Lakes, NJ)</td>
<td>50 units</td>
<td>0.5 mL</td>
<td align="center">—</td>
<td align="center">—</td>
</tr>
<tr>
<td>Magnesium sulfate 50%</td>
<td>APP Pharmaceuticals (Schaumburg, IL)</td>
<td>0.5 mEq</td>
<td>1.23 mL</td>
<td>11.13 (300)</td>
<td>0.014 (0.369)</td>
</tr>
<tr>
<td>Neotrace 4</td>
<td>American Regent, Inc (Shirley, NY)</td>
<td>0.2 mL<sup><xref ref-type="table-fn" rid="table-fn2-0148607111420154">b</xref></sup></td>
<td>0.2 mL</td>
<td>232 (6250)</td>
<td>0.046 (1.25)</td>
</tr>
<tr>
<td>Selenium, 40 µg/mL</td>
<td>American Regent, Inc</td>
<td>2 µg</td>
<td>0.05 mL</td>
<td>92.75 (2500)</td>
<td>0.005 (0.125)</td>
</tr>
<tr>
<td>Calcium chloride, 0.68 mmol/mL</td>
<td>Hospira, Inc</td>
<td>1.25 mmol<sup><xref ref-type="table-fn" rid="table-fn1-0148607111420154">a</xref></sup> (50 mg)</td>
<td>1.85 mL</td>
<td>37.1 (1000)</td>
<td>0.069 (1.85)</td>
</tr>
<tr>
<td>Sodium phosphate, 3 mmol/mL</td>
<td>Hospira, Inc</td>
<td>1.5 mmol<sup><xref ref-type="table-fn" rid="table-fn1-0148607111420154">a</xref></sup></td>
<td>0.5 mL</td>
<td>6.68 (180)</td>
<td>0.003 (0.09)</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0148607111420154">
<label>a</label>
<p>Dose used in aluminum study.</p>
</fn>
<fn id="table-fn2-0148607111420154">
<label>b</label>
<p>Contains Zn 300 µg, Cu 20 µg, Cr 0.17 µg, and Mn 5 µg.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>The sample solutions were stored at 37°C (±1°C) for 23–24 hours to simulate bedside environmental temperature and actual duration of hang time. Thorough visual inspection was performed to evaluate for the presence of precipitation. The first step in visual evaluation was inspection of the bag to identify solid precipitate formation in the bag. This was done with strong illumination against both light and dark backgrounds. Then, in a darkened room, a flashlight was used to shine light through the bag to further evaluate for precipitate. Finally, 20 mL of each solution was withdrawn and transferred to a clear, 30-mL glass vial and evaluated again for the presence of precipitate. One sample was done for each solution. Preparation and visualization of samples was performed by the same investigator and was not blinded. The whole process was repeated and a second sample was subjected to visual inspection to verify results when initial precipitation was observed for each AA concentration except the 1% solution. The preparation of repeat samples and visualization was performed by the same investigator who prepared and visualized the first sample, but a third investigator, a pharmacist, who was blinded to the process of preparation and initial visualization of the second sample, also conducted the visualization process on the repeat samples to verify precipitation results.</p>
<p>Study B was performed by a PharmD resident in March 2010 to determine Al concentrations in 3 PN solutions that were compounded in the pharmacy: S1 contained CaCl and NaPhos, S2 contained CaGlu and NaPhos, and S3 contained CaGlu and KPhos. Solutions were made using the additives and amounts shown in <xref ref-type="table" rid="table1-0148607111420154">Tables 1</xref> and <xref ref-type="table" rid="table2-0148607111420154">2</xref>. Al contents of the additives were derived from the manufacturers’ listed maximum content according to US Food and Drug Administration regulations on “Aluminum in Large and Small Volume Parenterals Used in Total Parenteral Nutrition.”<sup><xref ref-type="bibr" rid="bibr12-0148607111420154">12</xref>,<xref ref-type="bibr" rid="bibr13-0148607111420154">13</xref></sup> Five 100-mL aliquots of each of the 3 study PN solutions were compounded on 5 consecutive days. The 3-mL samples were drawn after thorough mixing by agitation and placed in acid-washed plastic tubes and frozen. Samples were sent frozen to NMS Labs (Willow Grove, PA). Al analysis was performed at NMS Labs in triplicate using inductively coupled mass spectrometry. Because the measured Al concentration in the initial 5 samples for S2 and S3 was significantly lower than predicted based on the manufacturers’ listed Al concentrations, we prepared 3 more samples of S2 and S3, which were acidified with 1% nitric acid to increase Al solubility in the samples, and sent them to NMS Labs for analysis.</p>
<table-wrap id="table2-0148607111420154" position="float">
<label>Table 2.</label>
<caption><p>Additional Additives for Aluminum Study</p></caption>
<graphic alternate-form-of="table2-0148607111420154" xlink:href="10.1177_0148607111420154-table2.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left">Additive</th>
<th align="center">Manufacturer</th>
<th align="center">Total Dose</th>
<th align="center">Volume Added</th>
<th align="center">Additive Aluminum Content, µmol/L (µg/L)</th>
<th align="center">Solution Aluminum Content, µmol/dL (µg/dL)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sterile water</td>
<td>Hospira, Inc (Lake Forest, IL)</td>
<td>QS to 100 mL</td>
<td>S1 = 47.9 mL</td>
<td>0.93 (25)</td>
<td>0.045 (1.20)</td>
</tr>
<tr>
<td/>
<td/>
<td/>
<td>S2 = 44.4 mL</td>
<td>0.93 (25)</td>
<td>0.041 (1.11)</td>
</tr>
<tr>
<td/>
<td/>
<td/>
<td>S3 = 44.4 mL</td>
<td>0.93 (25)</td>
<td>0.041 (1.11)</td>
</tr>
<tr>
<td>Infavite Pediatric (multivitamins)</td>
<td>Baxter Pharmaceuticals (Deerfield, IL)</td>
<td>1.5 mL</td>
<td>1.5 mL</td>
<td>1.11 (30)</td>
<td>0.002 (0.045)</td>
</tr>
<tr>
<td>Sodium acetate,2 mEq/mL</td>
<td>Hospira, Inc</td>
<td>2 mEq</td>
<td>1 mL</td>
<td>7.42 (200)</td>
<td>0.007 (0.200)</td>
</tr>
<tr>
<td>KCl, 2 mEq/mL</td>
<td>Hospira, Inc</td>
<td>1 mEq</td>
<td>0.5 mL</td>
<td>3.71 (100)</td>
<td>0.002 (0.05)</td>
</tr>
<tr>
<td>Calcium gluconate,0.23 mmol/mL</td>
<td>American Regent, Inc (Shirley, NY)</td>
<td>1.25 mmol (50 mg)</td>
<td>5.38 mL</td>
<td>349 (9400)</td>
<td>1.878 (50.57)</td>
</tr>
<tr>
<td>Potassium phosphate,3 mmol/mL</td>
<td>Hospira, Inc</td>
<td>1.5 mmol</td>
<td>0.5 mL</td>
<td>1373 (37,000)</td>
<td>0.687 (18.50)</td>
</tr>
</tbody>
</table>
</table-wrap>
<p>Both studies were approved by the Investigational Review Board at Providence St Vincent Medical Center. Because human subjects were not part of either study, informed consent was not required.</p>
</sec>
<sec id="section4-0148607111420154" sec-type="results">
<title>Results</title>
<p>In study A, 235 solutions were prepared and evaluated for precipitate. Maximum concentrations of CaCl that could be added to PN solutions without evidence of precipitation with varying concentrations of TrophAmine and NaPhos are shown in <xref ref-type="table" rid="table3-0148607111420154">Table 3</xref>. In the 1% TrophAmine solutions, precipitation became apparent with an elemental calcium concentration (as chloride) of 7.5 mmol/L (30 mg/dL) at all phosphate concentrations. As the concentration of AA increased, the amounts of calcium and phosphate that could be added without precipitation occurring also increased. In a 3% TrophAmine solution, a calcium concentration of 12.5 mmol/L (50 mg/dL) and a phosphate concentration of 15 mmol/L appeared compatible.</p>
<table-wrap id="table3-0148607111420154" position="float">
<label>Table 3.</label>
<caption><p>Maximum Calcium Chloride Concentrations (mmol/L) Allowable Without Precipitation at Various Amino Acid and Phosphate Concentrations</p></caption>
<graphic alternate-form-of="table3-0148607111420154" xlink:href="10.1177_0148607111420154-table3.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th/>
<th align="center" colspan="5">Sodium Phosphate</th>
</tr>
<tr>
<th align="left">Amino Acid, g/L (%)</th>
<th align="center">5 mmol/L</th>
<th align="center">7.5 mmol/L</th>
<th align="center">10 mmol/L</th>
<th align="center">15 mmol/L</th>
<th align="center">20 mmol/L</th>
</tr>
</thead>
<tbody>
<tr>
<td>10 (1.0)</td>
<td>5</td>
<td>5</td>
<td>5</td>
<td>5</td>
<td>5</td>
</tr>
<tr>
<td>15 (1.5)</td>
<td>7.5</td>
<td>7.5</td>
<td>7.5</td>
<td>7.5</td>
<td>5</td>
</tr>
<tr>
<td>20 (2.0)</td>
<td>12.5</td>
<td>12.5</td>
<td>12.5</td>
<td>7.5</td>
<td>5</td>
</tr>
<tr>
<td>25 (2.5)</td>
<td>12.5</td>
<td>12.5</td>
<td>12.5</td>
<td>10</td>
<td>5</td>
</tr>
<tr>
<td>28 (2.8)</td>
<td>12.5</td>
<td>12.5</td>
<td>12.5</td>
<td>10</td>
<td>5</td>
</tr>
<tr>
<td>30 (3.0)</td>
<td>12.5</td>
<td>12.5</td>
<td>12.5</td>
<td>12.5</td>
<td>7.5</td>
</tr>
<tr>
<td>35 (3.5)</td>
<td>12.5</td>
<td>12.5</td>
<td>12.5</td>
<td>12.5</td>
<td>7.5</td>
</tr>
<tr>
<td>40 (4.0)</td>
<td>12.5</td>
<td>12.5</td>
<td>12.5</td>
<td>12.5</td>
<td>7.5</td>
</tr>
</tbody>
</table>
</table-wrap>
<p>The results of study B of Al concentration in representative PN solutions are shown in <xref ref-type="table" rid="table4-0148607111420154">Table 4</xref>. One sample of S1 was reported back as showing no measured Al, so that sample was not included, leaving 4 samples for S1 and 8 samples for S2 and S3. There was no effect of acidification on the results for S2 and S3, so all results were included. Mean measured Al concentration for solutions made with CaGlu (S2) was 8.5 µmol/L (22.9 µg/dL) vs 2.2 µmol/L (6.0 µg/dL) for those made with CaCl (S1). When NaPhos was replaced with KPhos (S3), the Al concentration of solutions made with CaGlu increased to 11.7 µmol/L (31.5 µg/dL).</p>
<table-wrap id="table4-0148607111420154" position="float">
<label>Table 4.</label>
<caption><p>Calculated vs Measured Aluminum (Al) Concentrations</p></caption>
<graphic alternate-form-of="table4-0148607111420154" xlink:href="10.1177_0148607111420154-table4.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left">Study Solution</th>
<th align="center">S1:CaCl (1.25 mmol/dL)NaPhos (1.5 mmol/dL)</th>
<th align="center">S2:CaGlu (1.25 mmol/dL)NaPhos (1.5 mmol/dL)</th>
<th align="center">S3:CaGlu (1.25 mmol/dL)KPhos (1.5 mmol/dL)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Calculated [Al], µmol/L (µg/dL)</td>
<td>2.3 (6.3)</td>
<td>20.4 (54.9)</td>
<td>27.2 (73.3)</td>
</tr>
<tr>
<td>Measured [Al], mean ± SD, µmol/L (µg/dL)</td>
<td>2.2 ± 0.3 (6.0 ± 0.7)</td>
<td>8.5 ± 0.4 (22.9 ± 1.2)</td>
<td>11.7 ± 0.4 (31.5 ± 1.2)</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn3-0148607111420154">
<p>CaCl, calcium chloride; CaGlu, calcium gluconate; NaPhos, sodium phosphate; KPhos, potassium phosphate.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section5-0148607111420154" sec-type="discussion">
<title>Discussion</title>
<p>This article may provide guidance for practitioners who wish to use CaCl and NaPhos in TrophAmine-based PN solutions. Precipitation curves can be generated from the data in <xref ref-type="table" rid="table3-0148607111420154">Table 3</xref> to assist pharmacists in safely compounding TrophAmine-based PN solutions containing CaCl. As evidenced by the results of study A, increasing TrophAmine content increases the amounts of CaCl and NaPhos that can be added to the solution without precipitation. This result was expected because TrophAmine has a pH of 5.5 (5.0–6.0), and more acidic solutions as well as increased binding to AA allow for greater concentrations of calcium and phosphate in PN without precipitation.<sup><xref ref-type="bibr" rid="bibr8-0148607111420154">8</xref></sup> Two previous studies have reported results of precipitation studies of PN containing CaCl and NaPhos.<sup><xref ref-type="bibr" rid="bibr4-0148607111420154">4</xref>,<xref ref-type="bibr" rid="bibr11-0148607111420154">11</xref></sup> Different AA products were used in those studies. The more recent study by Bouchoud et al<sup><xref ref-type="bibr" rid="bibr11-0148607111420154">11</xref></sup> used a glucose concentration of 3 g/dL (3%) and an AA concentration of 0.4 g/dL (0.4%) because they were interested in studying conditions most favorable to precipitation. Consequently, calcium and phosphorus contents of the solutions they studied were restricted and did not meet the amounts required to meet recommended parenteral intakes for neonates of 1.5–2.0 mmol/kg/d (60–80 mg/kg/d of elemental Ca).<sup><xref ref-type="bibr" rid="bibr14-0148607111420154">14</xref></sup> In our neonatal units, as in many units at this time, it is standard to start a solution of 10% dextrose with 2 g/dL of AA (2%) at the time of admission for all infants ≤1500 g birth weight as well as other infants who are anticipated to require PN. Our patients, including term infants, requiring PN rarely receive PN solutions with amino acid concentrations &lt;2 g/dL (2%). Considering our actual practice with regard to PN, the data reported in our study provide a better guideline on which to base calcium and phosphorus concentrations in PN solutions.</p>
<p>CaGlu has been consistently identified as a source of significant Al contamination in PN.<sup><xref ref-type="bibr" rid="bibr15-0148607111420154">15</xref><xref ref-type="bibr" rid="bibr16-0148607111420154"/>–<xref ref-type="bibr" rid="bibr17-0148607111420154">17</xref></sup> Preterm infants who have been supported with PN containing high Al concentrations in which CaGlu is a major contributor of Al contamination have been shown to have elevated serum, plasma, and urine Al concentrations, as well as deposition in bone.<sup><xref ref-type="bibr" rid="bibr18-0148607111420154">18</xref><xref ref-type="bibr" rid="bibr19-0148607111420154"/>–<xref ref-type="bibr" rid="bibr20-0148607111420154">20</xref></sup> Al intake can be reduced to 0.1–0.2 µmol/kg/d (3–6 µg/kg/d) in preterm infants by reducing CaGlu content to 0.45–0.9 mmol/kg/d (18–36 mg/kg/d of elemental calcium), which is well below levels that provide the desired intakes of calcium for neonatal patients noted above.<sup><xref ref-type="bibr" rid="bibr21-0148607111420154">21</xref></sup> The authors reported no adverse effects due to Al on bone formation in that study, however.</p>
<p>Currently, the Food and Drug Administration (FDA) recommends limiting the Al intake from contamination of PN for preterm infants to ≤0.19 µmol/kg/d (≤5 µg/kg/d).<sup><xref ref-type="bibr" rid="bibr13-0148607111420154">13</xref></sup> Poole et al<sup><xref ref-type="bibr" rid="bibr22-0148607111420154">22</xref></sup> have shown that it is not possible to meet this goal and provide acceptable calcium and phosphorus intakes using neonatal PN solutions containing CaGlu and KPhos. We are able to significantly decrease Al exposure in our PN solutions containing CaCl and NaPhos while providing intakes of 1.25–1.75 mmol/kg/d (50–70 mg/kg/d) of calcium and 1.5–2 mmol/kg/d (48–64 mg/kg/d) of phosphorus with PN intakes of 100–140 mL/kg/d. Our PN solutions can meet the recommended parenteral intakes of calcium (60–80 mg/kg/d) and phosphorus (45–60 mg/kg/d)<sup><xref ref-type="bibr" rid="bibr14-0148607111420154">14</xref></sup> at PN fluid intakes of ≥120 mL/kg/d but will be below recommended intakes for calcium with fluid restriction below this level. The benefit of aluminum reduction in PN in infants needs to be weighed against the potential effects of decreased calcium that are provided in PN solutions using CaCl instead of CaGlu. The primary risk of decreased calcium and phosphorus intake is osteopenia of prematurity.<sup><xref ref-type="bibr" rid="bibr23-0148607111420154">23</xref></sup> However, for every day that preterm infants received high vs low Al-containing PN solutions, there was an estimated decrease of 1 point in the Bayley Mental Development Index score in the study by Bishop et al.<sup><xref ref-type="bibr" rid="bibr1-0148607111420154">1</xref></sup></p>
<p>Previous studies have shown that the measured Al concentrations in PN are significantly lower than calculated concentrations based on manufacturers’ reported Al contents of additives.<sup><xref ref-type="bibr" rid="bibr24-0148607111420154">24</xref>,<xref ref-type="bibr" rid="bibr25-0148607111420154">25</xref></sup> Although similar results were found for our high Al concentration study solutions containing CaGlu and KPhos, the measured Al concentrations in our low Al solution containing CaCl and NaPhos were almost identical to the calculated Al concentrations. The concentration of Al in our PN solution containing CaCl and NaPhos would allow Al intakes to approach intakes recommended by the FDA. Other sources may contribute to Al exposure in neonatal patients. Our solutions did not contain cysteine, which can contribute significantly to Al intake.<sup><xref ref-type="bibr" rid="bibr17-0148607111420154">17</xref></sup> Our decision to not routinely include cysteine in our PN solutions is also based on a meta-analysis of previous studies that indicates that there is a small improvement in nitrogen balance (equivalent to about 0.2 g/kg/d of protein) but no evidence of improved clinical outcomes or growth in preterm infants supplemented with L-cysteine in PN.<sup><xref ref-type="bibr" rid="bibr26-0148607111420154">26</xref></sup> In addition, although previous studies have indicated that cysteine may be a semi-essential AA for preterm infants, more recent studies suggest that preterm infants may have the capacity to synthesize cysteine.<sup><xref ref-type="bibr" rid="bibr27-0148607111420154">27</xref>,<xref ref-type="bibr" rid="bibr28-0148607111420154">28</xref></sup> Colloids can also contribute significantly to Al loading.<sup><xref ref-type="bibr" rid="bibr15-0148607111420154">15</xref></sup> Heparin was included in our solutions in study B, although some neonatal units may not include it in their PN solutions. The Al content of the heparin additive was not listed by the manufacturer and therefore was not included in the calculated Al content of the study solutions, but its contribution to the measured Al concentration of the study solutions would be included in our study. A previous study suggests that the Al content of heparin solutions is negligible, however.<sup><xref ref-type="bibr" rid="bibr15-0148607111420154">15</xref></sup></p>
<p>This study is not without limitations. The formula for each solution contained a limited number of ingredients. PN solutions prepared for an actual patient would likely include more ingredients that may affect the solubility of calcium and phosphate. We used a visual inspection method to detect the presence of precipitate. Microscopic inspection and photospectometry have been shown to be more sensitive for detecting the presence of precipitate.<sup><xref ref-type="bibr" rid="bibr29-0148607111420154">29</xref></sup> Although our studies are based on visual inspection methods, we have used the results to safely provide PN for multiple patients. It is also standard to use a 0.2-µm filter for all neonatal PN solutions, which would filter out any precipitate of a size believed to present a clinical risk. Our neonatal intensive care units compound a minimum total of 15 PN solutions per day. We have not experienced any complications or issues with regard to clogging of filters using an algorithm for calcium and phosphorus intakes in our PN calculator based on the data reported in <xref ref-type="table" rid="table3-0148607111420154">Table 3</xref>.</p>
</sec>
<sec id="section6-0148607111420154" sec-type="conclusions">
<title>Conclusion</title>
<p>Calcium-phosphate precipitation curves can be generated from the results of this study to help guide clinicians in compounding TrophAmine-based PN solutions containing CaCl and NaPhos to limit Al exposure in neonatal patients. Further studies are needed to verify the results of our precipitation studies and to determine the long-term effects of substituting CaCl for CaGlu in PN solutions in the neonatal population. Al exposure of neonatal patients can be reduced to near FDA guidelines by substituting CaCl and NaPhos for CaGlu and KPhos in PN.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="financial-disclosure">
<p>Financial disclosure: Materials and costs for the Aluminum measurements for the studies were funded by a research grant from Northwest Newborn Specialists, PC. TPN bags were provided by Baxa Corp. (Englewood, CO).</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0148607111420154">
<label>1.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bishop</surname><given-names>NJ</given-names></name>
<name><surname>Morley</surname><given-names>R</given-names></name>
<name><surname>Day</surname><given-names>JP</given-names></name>
<name><surname>Lucas</surname><given-names>A</given-names></name>
</person-group>. <article-title>Aluminum neurotoxicity in preterm infants receiving intravenous-feeding solutions</article-title>. <source>N Engl J Med</source>. <year>1997</year>;<volume>336</volume>(<issue>22</issue>):<fpage>1557</fpage>-<lpage>1561</lpage>.</citation>
</ref>
<ref id="bibr2-0148607111420154">
<label>2.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Fewtrell</surname><given-names>MS</given-names></name>
<name><surname>Bishop</surname><given-names>NJ</given-names></name>
<name><surname>Edmonds</surname><given-names>CJ</given-names></name>
<name><surname>Isaacs</surname><given-names>EB</given-names></name>
<name><surname>Lucas</surname><given-names>A</given-names></name>
</person-group>. <article-title>Aluminum exposure from parenteral nutrition in preterm infants: bone health at 15-year follow-up</article-title>. <source>Pediatrics</source>. <year>2009</year>;<volume>124</volume>:<fpage>1372</fpage>-<lpage>1379</lpage>.</citation>
</ref>
<ref id="bibr3-0148607111420154">
<label>3.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bohrer</surname><given-names>D</given-names></name>
<name><surname>do Nascimento</surname><given-names>PC</given-names></name>
<name><surname>Binotto</surname><given-names>R</given-names></name>
<name><surname>Becker</surname><given-names>E</given-names></name>
<name><surname>Pomblum</surname><given-names>S</given-names></name>
</person-group>. <article-title>Contribution of the raw material to the aluminum contamination in parenterals</article-title>. <source>JPEN J Parenter Enteral Nutr</source>. <year>2002</year>;<volume>26</volume>:<fpage>382</fpage>-<lpage>388</lpage>.</citation>
</ref>
<ref id="bibr4-0148607111420154">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Henry</surname><given-names>RS</given-names></name>
<name><surname>Jurgens</surname><given-names>RJ</given-names><suffix>Jr</suffix></name>
<name><surname>Sturgeon</surname><given-names>R</given-names></name>
<name><surname>Athanikar</surname><given-names>N</given-names></name>
<name><surname>Welco</surname><given-names>A</given-names></name>
<name><surname>Van Leuven</surname><given-names>M</given-names></name>
</person-group>. <article-title>Compatibility of calcium chloride and calcium gluconate with sodium phosphate in a mixed TPN solution</article-title>. <source>Am J Hosp Pharm</source>. <year>1980</year>;<volume>37</volume>(<issue>5</issue>):<fpage>673</fpage>-<lpage>674</lpage>.</citation>
</ref>
<ref id="bibr5-0148607111420154">
<label>5.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kaminski</surname><given-names>MV</given-names><suffix>Jr</suffix></name>
<name><surname>Harris</surname><given-names>DF</given-names></name>
<name><surname>Collin</surname><given-names>CF</given-names></name>
<name><surname>Sommers</surname><given-names>GA</given-names></name>
</person-group>. <article-title>Electrolyte compatibility in a synthetic amino acid hyperalimentation solution</article-title>. <source>Am J Hosp Pharm</source>. <year>1974</year>;<volume>31</volume>(<issue>3</issue>):<fpage>244</fpage>-<lpage>246</lpage>.</citation>
</ref>
<ref id="bibr6-0148607111420154">
<label>6.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Eggert</surname><given-names>LD</given-names></name>
<name><surname>Rusho</surname><given-names>WJ</given-names></name>
<name><surname>MacKay</surname><given-names>MW</given-names></name>
<name><surname>Chan</surname><given-names>GM</given-names></name>
</person-group>. <article-title>Calcium and phosphorus compatibility in parenteral nutrition solutions for neonates</article-title>. <source>Am J Hosp Pharm</source>. <year>1982</year>;<volume>39</volume>:<fpage>49</fpage>-<lpage>53</lpage>.</citation>
</ref>
<ref id="bibr7-0148607111420154">
<label>7.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Dunham</surname><given-names>BD</given-names></name>
<name><surname>Marcuard</surname><given-names>S</given-names></name>
<name><surname>Khazanie</surname><given-names>PG</given-names></name>
<name><surname>Meade</surname><given-names>G</given-names></name>
<name><surname>Craft</surname><given-names>T</given-names></name>
<name><surname>Nichols</surname><given-names>K</given-names></name>
</person-group>. <article-title>The solubility of calcium and phosphorous in neonatal total parenteral nutrition solutions</article-title>. <source>JPEN J Parenter Enteral Nutr</source>. <year>1991</year>;<volume>15</volume>:<fpage>608</fpage>-<lpage>611</lpage>.</citation>
</ref>
<ref id="bibr8-0148607111420154">
<label>8.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Newton</surname><given-names>DW</given-names></name>
<name><surname>Driscoll</surname><given-names>DF</given-names></name>
</person-group>. <article-title>Calcium and phosphate compatibility: revisited again</article-title>. <source>Am J Health Syst Pharm</source>. <year>2008</year>;<volume>65</volume>:<fpage>73</fpage>-<lpage>80</lpage>.</citation>
</ref>
<ref id="bibr9-0148607111420154">
<label>9.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hoie</surname><given-names>EB</given-names></name>
<name><surname>Narducci</surname><given-names>WA</given-names></name>
</person-group>. <article-title>Laser particle analysis of calcium phosphate precipitate in neonatal TPN admixtures</article-title>. <source>J Pediatr Pharm Pract</source>. <year>1996</year>;<volume>1</volume>(<issue>3</issue>):<fpage>163</fpage>-<lpage>167</lpage>.</citation>
</ref>
<ref id="bibr10-0148607111420154">
<label>10.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Fitzgerald</surname><given-names>KA</given-names></name>
<name><surname>MacKay</surname><given-names>MW</given-names></name>
</person-group>. <article-title>Calcium and phosphate solubility in neonatal parenteral nutrient solutions containing TrophAmine</article-title>. <source>Am J Hosp Pharm</source>. <year>1986</year>;<volume>43</volume>(<issue>1</issue>):<fpage>88</fpage>-<lpage>93</lpage>.</citation>
</ref>
<ref id="bibr11-0148607111420154">
<label>11.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bouchoud</surname><given-names>L</given-names></name>
<name><surname>Fonzo-Christe</surname><given-names>C</given-names></name>
<name><surname>Sadeghipour</surname><given-names>F</given-names></name>
<name><surname>Bonnabry</surname><given-names>P</given-names></name>
</person-group>. <article-title>Maximizing calcium and phosphate content in neonatal parenteral nutrition solutions using organic calcium and phosphate salts</article-title>. <source>JPEN J Parenter Enteral Nutr</source>. <year>2010</year>;<volume>34</volume>:<fpage>542</fpage>-<lpage>545</lpage>.</citation>
</ref>
<ref id="bibr12-0148607111420154">
<label>12.</label>
<citation citation-type="journal">
<collab>Food and Drug Administration</collab>. <article-title>Aluminum in large and small volume parenterals used in total parenteral nutrition</article-title>. <source>Fed Reg</source>. <year>2000</year>;<volume>65</volume>:<fpage>4103</fpage>-<lpage>4111</lpage>.</citation>
</ref>
<ref id="bibr13-0148607111420154">
<label>13.</label>
<citation citation-type="journal">
<collab>Food and Drug Administration</collab>. <article-title>Aluminum in large and small volume parenterals used in total parenteral nutrition; amendment; delay in effective date</article-title>. <source>Fed Reg</source>. <year>2002</year>;<volume>67</volume>:<fpage>70691</fpage>-<lpage>70692</lpage>.</citation>
</ref>
<ref id="bibr14-0148607111420154">
<label>14.</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Atkinson</surname><given-names>SA</given-names></name>
<name><surname>Tsang</surname><given-names>R</given-names></name>
</person-group>. <article-title>Calcium, magnesium, phosphorus, and vitamin D</article-title>. In: <person-group person-group-type="editor">
<name><surname>Tsang</surname><given-names>R</given-names></name>
<name><surname>Uauy</surname><given-names>R</given-names></name>
<name><surname>Koletzka</surname><given-names>B</given-names></name>
<name><surname>Zlotkin</surname><given-names>SH</given-names></name>
</person-group>, eds. <source>Nutrition of the Preterm Infant</source>. <publisher-loc>Cincinnati, OH</publisher-loc>: <publisher-name>Digital Educational Publishing</publisher-name>; <year>2005</year>:<fpage>245</fpage>-<lpage>275</lpage>.</citation>
</ref>
<ref id="bibr15-0148607111420154">
<label>15.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Koo</surname><given-names>WWK</given-names></name>
<name><surname>Kaplan</surname><given-names>LA</given-names></name>
<name><surname>Horn</surname><given-names>J</given-names></name>
<name><surname>Tsang</surname><given-names>RC</given-names></name>
<name><surname>Steichen</surname><given-names>JJ</given-names></name>
</person-group>. <article-title>Aluminum in parenteral nutrition solution-sources and possible alternatives</article-title>. <source>JPEN J Parenter Enteral Nutr</source>. <year>1986</year>;<volume>10</volume>:<fpage>591</fpage>-<lpage>595</lpage>.</citation>
</ref>
<ref id="bibr16-0148607111420154">
<label>16.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pluhator-Murton</surname><given-names>MM</given-names></name>
<name><surname>Fedorak</surname><given-names>RN</given-names></name>
<name><surname>Audette</surname><given-names>RJ</given-names></name>
<name><surname>Marriage</surname><given-names>BJ</given-names></name>
<name><surname>Yatscoff</surname><given-names>RW</given-names></name>
<name><surname>Gramlich</surname><given-names>LM</given-names></name>
</person-group>. <article-title>Trace element contamination of total parenteral nutrition, 1: contribution of component solutions</article-title>. <source>JPEN J Parenter Enteral Nutr</source>. <year>1999</year>;<volume>23</volume>:<fpage>222</fpage>-<lpage>227</lpage>.</citation>
</ref>
<ref id="bibr17-0148607111420154">
<label>17.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Smith</surname><given-names>BS</given-names></name>
<name><surname>Kothari</surname><given-names>H</given-names></name>
<name><surname>Hayes</surname><given-names>BD</given-names></name>
<etal/>
</person-group>. <article-title>Effect of additive selection on calculated aluminum content of parenteral nutrient solutions</article-title>. <source>Am J Health Syst Pharm</source>. <year>2007</year>;<volume>64</volume>:<fpage>730</fpage>-<lpage>739</lpage>.</citation>
</ref>
<ref id="bibr18-0148607111420154">
<label>18.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sedman</surname><given-names>AB</given-names></name>
<name><surname>Klein</surname><given-names>GL</given-names></name>
<name><surname>Merritt</surname><given-names>RJ</given-names></name>
<etal/>
</person-group>. <article-title>Evidence of aluminum loading in infants receiving intravenous therapy</article-title>. <source>N Engl J Med</source>. <year>1985</year>;<volume>312</volume>:<fpage>1337</fpage>-<lpage>1343</lpage>.</citation>
</ref>
<ref id="bibr19-0148607111420154">
<label>19.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Koo</surname><given-names>WWK</given-names></name>
<name><surname>Kaplan</surname><given-names>LA</given-names></name>
<name><surname>Krug-Wispe</surname><given-names>SK</given-names></name>
<name><surname>Succop</surname><given-names>P</given-names></name>
<name><surname>Bendon</surname><given-names>R</given-names></name>
</person-group>. <article-title>Response of preterm infants to aluminum in parenteral nutrition</article-title>. <source>JPEN J Parenter Enteral Nutr</source>. <year>1989</year>;<volume>13</volume>:<fpage>516</fpage>-<lpage>519</lpage>.</citation>
</ref>
<ref id="bibr20-0148607111420154">
<label>20.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>von Stockhausen</surname><given-names>HB</given-names></name>
<name><surname>Schrod</surname><given-names>L</given-names></name>
<name><surname>Brätter</surname><given-names>P</given-names></name>
<name><surname>Rösick</surname><given-names>U</given-names></name>
</person-group>. <article-title>Aluminum loading in premature infants during intensive care as related to clinical aspects</article-title>. <source>J Trace Elem Electrolytes Health Dis</source> <year>1990</year>;<volume>4</volume>:<fpage>209</fpage>-<lpage>213</lpage>.</citation>
</ref>
<ref id="bibr21-0148607111420154">
<label>21.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Naylor</surname><given-names>KE</given-names></name>
<name><surname>Eastell</surname><given-names>R</given-names></name>
<name><surname>Shattuck</surname><given-names>KE</given-names></name>
<name><surname>Alfrey</surname><given-names>AC</given-names></name>
<name><surname>Klein</surname><given-names>GL</given-names></name>
</person-group>. <article-title>Bone turnover in preterm infants</article-title>. <source>Pediatr Res</source>. <year>1999</year>;<volume>45</volume>:<fpage>363</fpage>-<lpage>366</lpage>.</citation>
</ref>
<ref id="bibr22-0148607111420154">
<label>22.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Poole</surname><given-names>RL</given-names></name>
<name><surname>Hintz</surname><given-names>SR</given-names></name>
<name><surname>Mackenzie</surname><given-names>NI</given-names></name>
<name><surname>Kerner</surname><given-names>JA</given-names></name>
</person-group>. <article-title>Aluminum exposure from parenteral nutrition: meeting the new FDA regulation</article-title>. <source>JPEN J Parenter Enteral Nutr</source>. <year>2008</year>;<volume>32</volume>:<fpage>242</fpage>-<lpage>246</lpage>.</citation>
</ref>
<ref id="bibr23-0148607111420154">
<label>23.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Harrison</surname><given-names>CM</given-names></name>
<name><surname>Johnson</surname><given-names>K</given-names></name>
<name><surname>McKechnie</surname><given-names>E</given-names></name>
</person-group>. <article-title>Osteopenia of prematurity: a national survey and review of practice</article-title>. <source>Acta Paediatrica</source>. <year>2008</year>;<volume>97</volume>:<fpage>407</fpage>-<lpage>413</lpage>.</citation>
</ref>
<ref id="bibr24-0148607111420154">
<label>24.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Speerhas</surname><given-names>RA</given-names></name>
<name><surname>Seidner</surname><given-names>DL</given-names></name>
</person-group>. <article-title>Measured versus estimated aluminum content of parenteral nutrient solutions</article-title>. <source>Am J Health Syst Pharm</source>. <year>2007</year>;<volume>64</volume>:<fpage>740</fpage>-<lpage>746</lpage>.</citation>
</ref>
<ref id="bibr25-0148607111420154">
<label>25.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Poole</surname><given-names>RL</given-names></name>
<name><surname>Schiff</surname><given-names>L</given-names></name>
<name><surname>Hintz</surname><given-names>SR</given-names></name>
<name><surname>Wong</surname><given-names>A</given-names></name>
<name><surname>Mackenzie</surname><given-names>N</given-names></name>
<name><surname>Kerner</surname><given-names>JA</given-names></name>
</person-group>. <article-title>Aluminum content of parenteral nutrition in neonates: measured versus calculated levels</article-title>. <source>J Pediatr Gastroenterol Nutr</source>. <year>2010</year>;<volume>50</volume>:<fpage>208</fpage>-<lpage>211</lpage>.</citation>
</ref>
<ref id="bibr26-0148607111420154">
<label>26.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Soghier</surname><given-names>LM</given-names></name>
<name><surname>Brion</surname><given-names>LP</given-names></name>
</person-group>. <article-title>Cysteine, cystine or N-acetylcysteine supplementation in parenterally fed neonates</article-title>. <source>Cochrane Database Syst Rev</source>. <year>2009</year>;(<issue>1</issue>):<comment>CD004869</comment>.</citation>
</ref>
<ref id="bibr27-0148607111420154">
<label>27.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Shew</surname><given-names>SB</given-names></name>
<name><surname>Keshen</surname><given-names>TH</given-names></name>
<name><surname>Jahoor</surname><given-names>F</given-names></name>
<name><surname>Jaksic</surname><given-names>T</given-names></name>
</person-group>. <article-title>Assessment of cysteine synthesis in very low-birth weight neonates using a [<sup>13</sup> C<sub>6</sub>] glucose tracer</article-title>. <source>J Pediatr Surg</source>. <year>2005</year>;<volume>40</volume>:<fpage>52</fpage>-<lpage>56</lpage>.</citation>
</ref>
<ref id="bibr28-0148607111420154">
<label>28.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Riedijk</surname><given-names>MA</given-names></name>
<name><surname>Voortman</surname><given-names>G</given-names></name>
<name><surname>van Beek</surname><given-names>RHT</given-names></name>
<name><surname>Baartmans</surname><given-names>MGA</given-names></name>
<name><surname>Wafelman</surname><given-names>LS</given-names></name>
<name><surname>van Goudoever</surname><given-names>JB</given-names></name>
</person-group>. <article-title>Cyst(e)ine requirements in enterally fed very low birth weight preterm infants</article-title>. <source>Pediatrics</source>. <year>2008</year>;<volume>121</volume>:<fpage>e561</fpage>-<lpage>e567</lpage>.</citation>
</ref>
<ref id="bibr29-0148607111420154">
<label>29.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Joy</surname><given-names>J</given-names></name>
<name><surname>Siilvestri</surname><given-names>AP</given-names></name>
<name><surname>Franke</surname><given-names>R</given-names></name>
<etal/>
</person-group>. <article-title>Calcium and phosphate compatibility in low-osmolarity parenteral nutrition admixtures intended for peripheral vein administration</article-title>. <source>JPEN J Parenter Enteral Nutr</source>. <year>2010</year>;<volume>34</volume>:<fpage>46</fpage>-<lpage>54</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>